R-biolin

About R-Bio

rBIO is a private, preclinical-stage biotech company aiming to disrupt the insulin market and bolster U.S. pharmaceutical supply chain resilience. Its core asset is a synthetic biology platform that reprograms microorganisms to produce therapeutic peptides, reportedly achieving double the insulin yield of traditional recombinant methods. The company's lead candidate, R-biolin, has demonstrated bioequivalence to Novolin R in preclinical studies and is being prepared for clinical trials and scale-up. rBIO's mission combines economic and national security objectives by targeting affordable drug production through domestic manufacturing.

Therapeutic Areas